麻豆亚洲精品在线播放,午夜在线视频91精品,麻豆视频一区二区,人人干在线观看,99久久精品国产免费,久久视频在线直播

最近，網(wǎng)絡(luò)上流傳著各種有關(guān)抗病毒藥物瑞德西韋臨床試驗(yàn)的消息，包括“藥物短時(shí)間內(nèi)已在761位患者身上全部顯效”等說法甚多，一時(shí)間令網(wǎng)友感到困惑。

Rumors began spreading online Thursday evening saying the US drug remdesivir had achieved a remarkable effect on 761 patients participating in the first day of the drug's clinical trial.

瑞德西韋是什么？什么時(shí)候進(jìn)行的試驗(yàn)？什么時(shí)候又能投入到使用中？伴隨著相關(guān)消息而來的則是大家的一連串疑問。

對(duì)此，中日友好醫(yī)院副院長曹彬教授于2月6日表示，有關(guān)瑞德西韋已經(jīng)通過臨床試驗(yàn)的說法不實(shí)：臨床研究今天才開始，怎么可能知道結(jié)果？

Cao Bin, vice-president of China-Japan Friendship Hospital and a scientist in charge of the research, said trials have only just started at a hospital in Wuhan, Hubei province, and no results have been achieved yet.


 
據(jù)新華網(wǎng)2月5日?qǐng)?bào)道，在科技部、國家衛(wèi)健委、國家藥監(jiān)局等多部門支持下，抗病毒藥物瑞德西韋（remdesivir）已完成臨床試驗(yàn)的注冊(cè)審批工作，第一批病例入組工作也已就位。首批新型冠狀病毒感染的肺炎重癥患者2月6日接受用藥。

The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday. The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.


2月5日，瑞德西韋臨床試驗(yàn)項(xiàng)目負(fù)責(zé)人、中日友好醫(yī)院副院長曹彬教授講解項(xiàng)目內(nèi)容。新華社記者 程敏 攝

瑞德西韋臨床試驗(yàn)項(xiàng)目負(fù)責(zé)人、中日友好醫(yī)院副院長曹彬教授，在武漢市金銀潭醫(yī)院召開的科技部應(yīng)急攻關(guān)“瑞德西韋治療2019新型冠狀病毒感染研究”項(xiàng)目啟動(dòng)會(huì)上介紹，瑞德西韋是美國吉利德公司的在研藥物，在前期的細(xì)胞和動(dòng)物實(shí)驗(yàn)中均顯示出對(duì)SARS冠狀病毒、MERS冠狀病毒有較好的抗病毒活性，國外已開展瑞德西韋針對(duì)埃博拉冠狀病毒感染的臨床試驗(yàn)。

Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, said Cao Bin, head of the drug's clinical trial program, at the conference held by the MOST at the Wuhan Jinyintan Hospital, central China's Hubei Province. The drug has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments. Its clinical trials against Ebola infections have been conducted abroad. 

近日，我國學(xué)者報(bào)道瑞德西韋在細(xì)胞水平上對(duì)2019新型冠狀病毒也有較好的活性。

In related domestic research, it has also shown fairly good antiviral activity against the 2019-nCoV at the cellular level, said Cao.

中國工程院副院長、中國醫(yī)學(xué)科學(xué)院院長王辰院士在啟動(dòng)會(huì)上表示，各界對(duì)這一試驗(yàn)有期望，但有無效果，還需要等待嚴(yán)格的科學(xué)試驗(yàn)結(jié)果。瑞德西韋臨床試驗(yàn)由中日友好醫(yī)院、中國醫(yī)學(xué)科學(xué)院藥物研究所牽頭，研究將在武漢金銀潭醫(yī)院等多家臨床一線接診新型冠狀病毒感染肺炎患者的醫(yī)院中進(jìn)行，擬入組761例患者，采用隨機(jī)、雙盲、安慰劑對(duì)照方法展開。

A total of 761 patients have been enrolled in the trials, which will adopt a randomized, double-blind and placebo-controlled study method. The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), will be conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital. Hopes have been pinned on the drug, but we have to wait for results of its actual effectiveness in the clinical trials, said Wang Chen, vice president of the Chinese Academy of Engineering and president of the CAMS.


2月5日，中國工程院副院長、中國醫(yī)學(xué)科學(xué)院院長王辰院士（右一）介紹項(xiàng)目情況。 新華社記者 程敏 攝

據(jù)中國日?qǐng)?bào)網(wǎng)報(bào)道，1月底吉利德公司發(fā)布聲明，表示瑞德西韋尚未獲得進(jìn)入任何國家市場的許可，藥物的安全性和有效性還有待證實(shí)。

In a statement at the end of last month, Gilead said Remdesivir had not gained approval to enter the market in any country, and its safety and effectiveness had not yet been proven.

此前，中日友好醫(yī)院曾對(duì)外介紹，該項(xiàng)臨床研究計(jì)劃的結(jié)束時(shí)間是4月27日。

綜合來源：新華網(wǎng)，中國日?qǐng)?bào)網(wǎng)，CGTN